1 / 5

Global Pharmaceutical Contract Manufacturing Market

The Pharmaceutical Contract Development and Manufacturing Market is expected to grow at a CAGR of 7.5% from 2022 to 2029 to reach $226.35 billion by 2029. Pharma contract manufacturing companies offer various services to drug companies. The growth of this market is mainly driven by the complex manufacturing requirements of the pharmaceutical industry, increasing investments in pharmaceutical R&D, the pharmaceutical industryu2019s growing inclination towards cutting-edge technologies, patent expiration, and the coronavirus pandemic. In addition, the growing demand for cell and gene therapies and pe

Kavya53
Télécharger la présentation

Global Pharmaceutical Contract Manufacturing Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Pharmaceutical Contract Development and Manufacturing Market Worth $226.35 Billion by 2029

  2. Pharmaceutical Contract Development and Manufacturing Market worth $226.35 Billion by 2029 The Pharmaceutical Contract Development and Manufacturing Market is expected to grow at a CAGR of 7.5% from 2022 to 2029 to reach $226.35 billion by 2029. Pharma contract manufacturing companies offer various services to drug companies. The growth of this market is mainly driven by the complex manufacturing requirements of the pharmaceutical industry, increasing investments in pharmaceutical R&D, the pharmaceutical industry’s growing inclination towards cutting-edge technologies, patent expiration, and the coronavirus pandemic. In addition, the growing demand for cell and gene therapies and personalized medicines and the growth of the High-potency Active Pharmaceutical Ingredients (HPAPI) and Antibody-drug Conjugates (ADC) markets is expected to offer significant opportunities for the players operating in this market. However, the lack of skilled professionals and the introduction of serialization are key factors expected to hinder the growth of the pharmaceutical contract development and manufacturing market. To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/pharmaceutical-contract-development-and- manufacturing-market-5171 Pharmaceutical Contract Development and Manufacturing Market: Future Outlook The pharmaceutical contract development and manufacturing market is segmented based on Service {Manufacturing [API, FDF (Parenteral, Injectable, Tablet, Capsule, Oral Liquid)], Drug Development, Biologics Manufacturing}, End User [Large Pharma, Generic] and Geography. The study also evaluates industry competitors and analyzes their market shares at the global and regional levels. Based on service, in 2022, the pharmaceutical manufacturing services segment is estimated to account for the largest share of the pharmaceutical contract development and manufacturing market. The large share of this segment is attributed to factors such as the use of advanced technologies and skills for pharmaceutical manufacturing, the growing need to reduce manufacturing costs, the need for high-quality bulk manufacturing, and the increasing demand for generic drugs. Page 1 of 4 © Meticulous Research| sales@meticulousresearch.com

  3. Pharmaceutical Contract Development and Manufacturing Market worth $226.35 Billion by 2029 Download Sample Copy Here: https://www.meticulousresearch.com/download-sample- report/cp_id=5171 Based on end user, in 2022, the large pharmaceutical companies segment is estimated to account for the largest share of the pharmaceutical contract development and manufacturing market. The large share of this segment is attributed to factors such as the rising incidence and prevalence of various diseases resulting in the increased demand for effective medicines and biopharmaceutical products, the growing need for state-of-the-art production processes and technologies, and the increasing costs of clinical trials and early development studies, leading to increased collaborations between pharmaceutical companies and contract manufacturers. Geographic Review: This research report analyzes major geographies and provides a comprehensive analysis of North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain and RoE), Asia-Pacific (China, Japan, India, and RoAPAC), Latin America (Brazil, Mexico, RoLATAM), and the Middle East & Africa. In 2022, North America is expected to account for the largest share of the pharmaceutical contract development and manufacturing market, followed by Europe and Asia-Pacific. However, Asia- Pacific is slated to register the highest CAGR during the forecast period. The high market growth in Asia-Pacific is driven by factors such as increasing government focus on the pharmaceutical sector, growth of the region’s manufacturing sector, and the rising incidence & prevalence of chronic illnesses. In addition, rising health awareness and treatment availability, low cost of manufacturing, and increased outsourcing of clinical activities are estimated to contribute to the growth of this regional market during the forecast period. Customize My Report:https://www.meticulousresearch.com/request- customization/cp_id=5171 Key Players: The key players operating in the pharmaceutical contract development and manufacturing market are Thermo Fisher Scientific Inc. (U.S.), Catalent Inc. (U.S.), Lonza Group Ltd (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GmbH (Germany) Piramal Enterprises Limited (India), Almac Group (U.K.), Cambrex Corporation (U.S.), Samsung Biologics Co., Ltd (South Korea), Siegfried Holding AG (Switzerland), FUJIFILM Diosynth Biotechnologies (Japan), Aenova Group (Germany), C.H. Boehringer Sohn AG & Co. KG (Germany), by Fareva SA (Luxembourg), Fabbrica Italiana Sintetici S.p.A. (Italy), WuXi Biologics (Cayman) Inc. (China), and Aurobindo Pharma Ltd. (India). Buy Now:https://www.meticulousresearch.com/Checkout/67156803 Scope of the Report: Page 2 of 4 © Meticulous Research| sales@meticulousresearch.com

  4. Pharmaceutical Contract Development and Manufacturing Market worth $226.35 Billion by 2029 Pharmaceutical Contract Development and Manufacturing Market, by Service •Pharmaceutical Manufacturing Services oAPI Manufacturing Services oFDF Manufacturing Services ▪Parenteral/Injectable Manufacturing Services ▪Tablet Manufacturing Services ▪Capsule Manufacturing Services ▪Oral Liquid Manufacturing Services ▪Other Formulations Manufacturing Services •Drug Development Services •Biologics Manufacturing Services oAPI Manufacturing Services oFDF Manufacturing Services •Packaging Services Pharmaceutical Contract Development and Manufacturing Market, by End User •Large Pharmaceutical Companies •Small and Mid-size Pharmaceutical Companies •Generic Pharmaceutical Companies Pharmaceutical Contract Development and Manufacturing Market, by Geography •North America oU.S. oCanada •Europe oGermany oU.K. oFrance oItaly oSpain oSwitzerland oRest of Europe (RoE) •Asia-Pacific (APAC) oChina oJapan oIndia oRest of APAC (RoAPAC) •Latin America Page 3 of 4 © Meticulous Research| sales@meticulousresearch.com

  5. Pharmaceutical Contract Development and Manufacturing Market worth $226.35 Billion by 2029 oBrazil oMexico oRest of Latin America •Middle East & Africa Contact Us: Meticulous Research® Email- sales@meticulousresearch.com Contact Sales- +1-646-781-8004 Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research Page 4 of 4 © Meticulous Research| sales@meticulousresearch.com

More Related